Title |
Treatment with echinocandins during continuous renal replacement therapy
|
---|---|
Published in |
Critical Care, March 2014
|
DOI | 10.1186/cc13803 |
Pubmed ID | |
Authors |
Francisco Javier González de Molina, MariadeLosÁngeles Martínez-Alberici, Ricard Ferrer |
Abstract |
Echinocandins are indicated as first-line treatment for invasive candidiasis in moderate to severe illness. As sepsis is the main cause of acute kidney injury, the combination of echinocandin treatment and continuous renal replacement therapy (CRRT) is common. Optimizing antibiotic dosage in critically ill patients receiving CRRT is challenging. The pharmacokinetics of echinocandins have been studied under various clinical conditions; however, data for CRRT patients are scarce. Classically, drugs like echinocandins with high protein binding and predominantly non-renal elimination are not removed by CRRT, indicating that no dosage adjustment is required. However, recent studies report different proportions of echinocandins lost by filter adsorption. Nevertheless, the clinical significance of these findings remains unclear. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 2 | 40% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 80% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 2% |
Italy | 1 | 2% |
Unknown | 40 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 8 | 19% |
Researcher | 8 | 19% |
Student > Ph. D. Student | 6 | 14% |
Student > Doctoral Student | 4 | 10% |
Student > Postgraduate | 4 | 10% |
Other | 5 | 12% |
Unknown | 7 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 26 | 62% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
Immunology and Microbiology | 1 | 2% |
Psychology | 1 | 2% |
Unknown | 11 | 26% |